Roche Strikes Reality Note For Production Of Regeneron-Partnered COVID-19 Antibody Cocktail
Manufacturing A Massive Challenge
Roche Pharma CEO Bill Anderson is excited about the prospects for REGN-COV2 but with the company and Regeneron possibly producing two million doses per year by the end of Q1 2021, meeting demand worldwide will be an impossible task.
